Who are DC-806's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Induction- PF-06480605 450 mg SC Q4W.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dc-806.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DC-806 — Competitive Intelligence Brief

DC-806 (DC-806) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17 receptor antagonist. Area: Inflammatory diseases.

phase 2 IL-17 receptor antagonist IL-17 receptor Inflammatory diseases Small molecule Live · refreshed every 30 min

Target snapshot

DC-806 (DC-806) — DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DC-806 TARGET	DC-806	DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company	phase 2	IL-17 receptor antagonist	IL-17 receptor
Induction- PF-06480605 450 mg SC Q4W	induction-pf-06480605-450-mg-sc-q4w	Pfizer	marketed	small molecule	IL-17 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17 receptor antagonist class)

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DC-806 — Competitive Intelligence Brief. https://druglandscape.com/ci/dc-806. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab